查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924681

吸入式SEVOFLURANE麻醉劑市場依給藥途徑、病患年齡層、劑型、最終用戶、通路及應用分類－2026-2032年全球預測

Inhalation Sevoflurane Anaesthetic Agent Market by Delivery Mode, Patient Age Group, Formulation, End User, Distribution Channel, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，吸入式SEVOFLURANE麻醉劑市場價值將達到 10.7 億美元，到 2026 年將成長至 11.8 億美元，到 2032 年將達到 22 億美元，複合年成長率為 10.76%。

關鍵市場統計數據
基準年 2025 10.7億美元
預計年份：2026年 11.8億美元
預測年份 2032 22億美元
複合年成長率 (%) 10.76%

從策略觀點探討SEVOFLURANE的臨床效用、生產考量、監管壓力以及影響當前決策的相關人員

本執行摘要概述了SEVOFLURANE（一種廣泛使用的揮發性吸入麻醉劑）的臨床、商業性和供應現狀。SEVOFLURANE因其優異的藥物動力學特性、快速起效和恢復以及在各種手術環境中良好的安全性記錄，長期以來一直是麻醉護理中常用的藥物。同時，蒸發器技術的進步、製劑穩定性的提高以及監管力度的加強，對生產商、經銷商和臨床用戶都提出了新的營運要求。這些因素促使人們需要對產品生命週期進行更全面的觀點，涵蓋從合成和純度控制到給藥方式相容性和環境因素等各個方面。

技術、環境、監管和臨床工作流程的變化如何重塑SEVOFLURANE的供應、採購模式以及供應商與客戶的關係

吸入麻醉劑領域正經歷變革，其驅動力包括技術進步、永續性需求以及不斷演進的臨床工作流程。新型輸送平台和蒸發器創新正在重塑SEVOFLURANE的給藥方式，實現更精準的劑量調整、簡化與麻醉資訊管理系統的整合，並拓展傳統手術室以外的行動應用場景。同時，監管機構對環境影響和微量雜質的審查日益嚴格，加速了對更環保的生產流程和封閉式輸送技術的投資。這些變革並非孤立發生，而是波及採購政策、醫院處方集和培訓項目，促使醫療機構重新評估其設備庫存和臨床指南。

了解近期美國關稅變化對SEVOFLURANE供應鏈、採購慣例和分銷模式的累積營運和合約影響

2025年，美國關稅調整為吸入麻醉劑相關設備的製造商、進口商和下游採購商帶來了累積營運方面的考量。關稅變化加劇了全球供應鏈的成本壓力，尤其是在原料採購、中間化學加工或成品進口涉及跨境環節的情況下。雖然擁有本地生產的垂直整合型製造商能夠減輕部分影響，但依賴跨境分銷的公司則面臨更高的到岸成本和複雜的海關合規義務。這種環境迫使採購部門實現供應商多元化，最佳化籌資策略，並重新評估在貿易夥伴之間分擔關稅風險的合約條款。

基於詳細細分的洞察，將最終用戶需求、手術應用、給藥方式、患者人口統計特徵、通路和製劑形式與策略決策聯繫起來

精細化的市場細分分析揭示了臨床、交付和商業性邊界如何影響產品設計、通路策略和客戶參與。依照最終用戶分析市場，門診手術中心、診所和醫院構成了不同的需求群體。醫院附屬和獨立的門診手術中心優先考慮快速周轉率和可預測的復健過程，而跨境的人類和獸醫診所則優先考慮便攜性和便利的管理。醫院（包括私立和公立醫院）既要應對大量的急診需求，又要管理複雜的處方箋和嚴格的採購週期，因此需要可靠的供應和合規的文件記錄。

美洲、歐洲、中東和非洲以及亞太地區的區域醫療保健結構、監管差異、採購慣例和臨床培訓生態系統帶來了不同的機會和限制。

區域趨勢持續對吸入麻醉劑的可近性、監管和臨床醫生偏好產生深遠影響。在美洲，大規模三級醫院和不斷擴展的門診中心網路構成了一個醫療保健系統，該系統推動了對能夠支援高吞吐量和快速周轉率的解決方案的需求。報銷結構和採購政策決定了各機構採用的給藥系統和製劑，而半球內部的跨境貿易流動則影響著製造商和經銷商的採購決策。

透過配方管理、霧化器和設備整合夥伴關係、監管應對力以及以永續性為中心的製造和服務模式實現競爭差異化

吸入麻醉劑及其給藥系統的競爭格局涵蓋了成熟的製藥企業、專業器械製造商以及專注於新型蒸發器和封閉式給藥系統的新興技術參與企業。主要企業透過投資配方穩定性、生產控制（以最大限度減少雜質）、蒸發器相容性以及服務系統來實現差異化競爭。化學品製造商和器械製造商之間的策略聯盟日益普遍，從而能夠提供捆綁式解決方案，簡化醫院和手術中心的採購和維護流程。

針對製造商、經銷商和臨床領導者的具體建議，以加強其供應鏈，使其產品系列與工作流程保持一致，並提高監管和商業性準備。

產業領導者應優先採取一系列切實可行的措施，以增強韌性、推動應用普及並在臨床環境中創造價值。首先，投資於價值鏈透明度和供應商多元化，以降低跨境關稅和海關政策差異的風險，並考慮本地化或契約製造方案以提高應對力。其次，設計與醫院和門診護理工作流程相契合的產品系列。這包括提供即用型溶液和帶閥藥筒等劑型，並確保其與機械式和手持式霧化器平台相容。

一項多學科研究設計結合了對臨床和採購負責人的訪談、現場觀察、法規和技術審查以及供應鏈分析，以進行三角驗證和結論確認。

本調查方法結合了質性研究、量化文獻分析和監管審查，建構了強而有力的三角驗證證據基礎。質性研究包括對臨床麻醉醫師、手術全期護理師、醫院藥師、採購經理和醫療設備技術人員進行結構化訪談，以了解操作流程、臨床偏好和採購限制。此外，還對門診中心和醫院手術全期科室進行了實地考察，觀察器械整合、工作流程協調以及實際臨床用藥和恢復模式。

整合臨床、商業性和營運方面的必要因素，制定相關人員應對SEVOFLURANE供應、監管和應用趨勢變化的準備策略。

總之，儘管SEVOFLURANE仍然是現代麻醉護理的基石，但其商業性和營運環境正隨著技術、政策和臨床工作流程的不斷發展而改變。積極調整產品開發和分銷策略以適應細分市場實際情況（包括終端用戶多樣性、特定應用需求、給藥方式相關人員、患者人口統計因素、通路要求和製劑要求）的利益相關者，將更有利於滿足機構採購標準和臨床醫生的期望。同時，關稅趨勢和區域監管差異凸顯了供應鏈韌性和靈活製造地的重要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 吸入式SEVOFLURANE麻醉劑市場依給藥方式分類

  • 手持式霧化器
  • 機械化油器
  • 攜帶式吸入器

9. 依患者年齡層分類的吸入式SEVOFLURANE麻醉劑市場

  • 成人版
  • 老年人
  • 兒童

10. 吸入型SEVOFLURANE麻醉劑市場（依劑型分類）

  • 濃縮液液
  • 預先閥門式墨盒
  • 即用型解決方案

第11章 吸入式SEVOFLURANE麻醉劑市場（依最終用戶分類）

  • 門診手術中心
  • 診所
    • 人類診所
    • 獸醫診所
  • 醫院
    • 私人的
    • 民眾

12. 吸入式SEVOFLURANE麻醉劑市場依通路分類

  • 離線
  • 線上

13. 吸入式SEVOFLURANE麻醉劑市場依應用領域分類

  • 心臟手術
  • 一般外科
    • 腹部
    • 耳鼻喉科
    • 整形外科
  • 神經外科
  • 婦產科
  • 兒童外科

14. 各地區吸入式SEVOFLURANE麻醉劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

15. 吸入式SEVOFLURANE麻醉劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國吸入式七SEVOFLURANE麻醉劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國吸入式SEVOFLURANE麻醉劑市場

第18章：中國吸入式SEVOFLURANE麻醉劑市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3S Corporation
  • AbbVie Inc.
  • Aetos Pharma Private Limited
  • Baxter International Inc.
  • Cadila Healthcare Ltd.
  • Central Glass Co., Ltd.
  • Fresenius Kabi AG
  • Halocarbon Products Corporation
  • Hikma Pharmaceuticals PLC
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Lunan Pharmaceutical Group Co., Ltd.
  • Neon Laboratories Pvt. Ltd.
  • Novartis AG
  • Novartis India Limited
  • Ocean Pharmaceutical Ltd.
  • Piramal Enterprises Ltd.
  • Raman & Weil Private Limited
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Sandoz Group AG
  • Troikaa Pharmaceuticals Ltd.
Product Code: MRR-7A380DA7C41F

The Inhalation Sevoflurane Anaesthetic Agent Market was valued at USD 1.07 billion in 2025 and is projected to grow to USD 1.18 billion in 2026, with a CAGR of 10.76%, reaching USD 2.20 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.07 billion
Estimated Year [2026] USD 1.18 billion
Forecast Year [2032] USD 2.20 billion
CAGR (%) 10.76%

A strategic orientation to sevoflurane's clinical utility, manufacturing considerations, regulatory pressures, and stakeholder drivers shaping present-day decisions

This executive summary introduces the clinical, commercial, and supply landscape surrounding sevoflurane, a widely used volatile inhalation anesthetic. Over time, sevoflurane's favorable pharmacokinetic profile, rapid onset and recovery characteristics, and established safety record in diverse surgical contexts have solidified its position in anesthetic practice. Concurrent advances in vaporizer technology, formulation stability, and regulatory scrutiny have created new operational demands for manufacturers, distributors, and clinical users alike. These forces have encouraged a more integrated view of product lifecycles, from synthesis and purity control to delivery mode compatibility and environmental stewardship.

Clinicians increasingly weigh patient throughput and recovery metrics alongside clinical efficacy, which has altered perioperative workflows and device interoperability requirements. At the same time, regulatory agencies are intensifying attention on trace impurities, greenhouse gas reporting, and end-of-life disposal for inhalational agents. This introduction sets the stage for the subsequent sections by outlining the principal drivers that shape supply chain resiliency, adoption pathways across care settings, and the competitive behaviors of pharmaceutical and device companies operating in this therapeutic domain. The aim is to equip decision-makers with a cohesive framing that supports deeper interrogation of segmentation, regional dynamics, tariff implications, and actionable responses.

How technological, environmental, regulatory, and clinical workflow shifts are reshaping sevoflurane delivery, procurement models, and supplier-customer relationships

The inhalational anesthetic landscape is undergoing transformative shifts driven by technological refinement, sustainability imperatives, and evolving clinical workflows. New delivery platforms and vaporizer innovations are reshaping how sevoflurane is administered, enabling more precise dosing, simplified integration with anesthesia information management systems, and enhanced mobile use cases outside traditional operating rooms. At the same time, heightened regulatory scrutiny on environmental impact and trace impurities has accelerated investments in greener manufacturing processes and closed-system delivery technologies. These changes do not occur in isolation; rather, they cascade across purchasing policies, hospital formularies, and training programs, prompting institutions to reassess equipment inventories and clinical guidelines.

Additionally, the convergence of veterinary and human clinical needs is prompting cross-pollination of best practices, particularly in portable inhalation systems and rapid induction protocols. Digital health integrations, such as anesthesia depth monitoring and predictive analytics, are elevating expectations for compatibility between anesthetic agents and monitoring platforms. As a result, suppliers are shifting from transactional product sales toward bundled solutions that combine agent availability, device support, and lifecycle service agreements. This transformation creates both opportunities and complexities for stakeholders seeking to balance clinical excellence, cost containment, and compliance obligations across diverse care settings.

Understanding the cumulative operational and contractual repercussions from recent United States tariff shifts on sevoflurane supply chains, procurement practices, and distribution models

In 2025, tariff adjustments in the United States have created a cumulative set of operational considerations for manufacturers, importers, and downstream purchasers of inhalational anesthetics and related equipment. Tariff changes have increased the cost pressure on global supply chains where raw material sourcing, intermediate chemical processing, or finished-product imports cross tariff boundaries. Manufacturers with vertically integrated local production have been able to mitigate some exposure, while those dependent on cross-border component flows face higher landed costs and more complex customs compliance obligations. This environment has pushed procurement teams to reassess supplier diversification, preferential sourcing strategies, and contractual terms that allocate tariff risk across trading partners.

Hospitals and ambulatory centers are responding by tightening inventory management, re-evaluating just-in-time deliveries, and seeking longer-term supply agreements that include price adjustment mechanisms tied to policy changes. Distribution channels have also adapted, with wholesale distributors and online pharmacy platforms building tariff contingencies into their logistics and contractual frameworks. Parallel to commercial adjustments, regulatory stakeholders and industry associations have called for clearer tariff classifications for specialty chemicals and finished inhalation formulations to reduce ambiguity. Collectively, these developments have encouraged stakeholders to pursue closer collaboration with customs experts, explore regional manufacturing footprints, and incorporate tariff scenario planning into strategic procurement and capital equipment decisions.

Detailed segmentation-driven insights connecting end-user requirements, surgical applications, delivery modes, patient cohorts, distribution channels, and formulation formats to strategic decisions

A granular segmentation lens reveals how clinical, delivery, and commercial boundaries inform product design, channel strategy, and customer engagement. When markets are analyzed by end user, ambulatory surgery centers, clinics, and hospitals emerge as discrete demand pools; ambulatory surgery centers, which can be hospital affiliated or standalone, emphasize fast turnover and predictable recovery profiles, while clinics-spanning both human and veterinary practices-prioritize portability and simplified administration. Hospitals, whether private or public, combine high-volume acute needs with complex formulary governance and stringent procurement cycles, which in turn demands robust supply reliability and compliance documentation.

Examining application-based segmentation highlights how surgical specializations shape anesthetic selection and delivery preferences. Cardiac, neurological, obstetric and gynecologic, pediatric, and general surgeries each present distinct hemodynamic and recovery considerations, with general surgery workflows subdividing into abdominal, ear nose and throat, and orthopedic procedures that influence agent choice and delivery apparatus. Delivery mode segmentation-covering handheld vaporizers, machine vaporizers, and portable inhalers-directly drives interoperability requirements and training needs for anesthesia teams. Patient age group analysis shows adult, geriatric, and pediatric cohorts necessitate tailored dosing strategies, monitoring parameters, and recovered-care pathways. Distribution channel segmentation, spanning hospital pharmacies, online pharmacies, and wholesale distributors, shapes lead times, contract terms, and compliance checkpoints. Finally, formulation segmentation-encompassing liquid concentrates, pre-valved cartridges, and ready-to-use solutions-guides cold chain considerations, shelf-life management, and compatibility with diverse vaporizer technologies. Synthesizing these segmentation perspectives yields actionable insights for product positioning, clinical education, and commercial channel optimization.

How regional healthcare structures, regulatory variance, procurement practices, and clinical training ecosystems create distinct opportunities and constraints across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to exert a profound influence on accessibility, regulation, and clinician preferences related to inhalational anesthetics. In the Americas, healthcare systems balance large tertiary care hospitals with a growing network of ambulatory centers, driving demand for solutions that support high throughput and rapid turnover. Reimbursement structures and procurement policies shape which delivery systems and formulations institutions adopt, and cross-border trade flows within the hemisphere affect sourcing decisions for manufacturers and distributors.

In Europe, the Middle East & Africa, regulatory harmonization efforts coexist with highly fragmented market access pathways, creating a landscape where environmental reporting, impurity thresholds, and single-use device policies vary significantly. This fragmentation favors suppliers who offer comprehensive regulatory support and adaptable packaging and logistics solutions. The Asia-Pacific region presents a spectrum from high-volume public hospitals to rapidly expanding private specialty clinics; growth in surgical capacity, investment in perioperative technologies, and domestic manufacturing initiatives influence both supply dynamics and competitive positioning. Across regions, differences in clinical training, anesthesia workforce distribution, and capital equipment lifecycles inform adoption timing and the types of partnerships that suppliers prioritize. Appreciating these regional nuances is essential for aligning product portfolios, regulatory strategies, and commercial models to local health system realities.

Competitive differentiation through formulation control, integrated vaporizer-device partnerships, regulatory readiness, and sustainability-focused manufacturing and service models

The competitive landscape for inhalational anesthetic agents and their delivery systems encompasses established pharmaceutical manufacturers, specialized device makers, and emerging technology entrants focused on novel vaporizers and closed delivery systems. Leading companies differentiate through formulation stability, manufacturing controls that minimize impurities, and investments in vaporizer compatibility and service ecosystems. Strategic partnerships between chemical producers and device manufacturers are increasingly common, enabling bundled offerings that simplify procurement and maintenance for hospitals and surgery centers.

Innovation pathways include advances in cartridge-based pre-dosed systems, ready-to-use solutions that reduce preparation time, and portable devices that expand anesthesia delivery into ambulatory and outpatient settings. Companies that combine robust regulatory pathways with lifecycle service agreements and training support find greater receptivity among institutional purchasers. In addition, sustainability initiatives, such as reduced-emission inhalational systems and greener manufacturing processes, are creating new vectors for differentiation. Competitive strategies also involve geographic manufacturing footprints that mitigate tariff exposure and supply chain disruptions, along with distribution partnerships that broaden reach into online pharmacy channels and wholesale networks. Stakeholders evaluating competitive positioning should emphasize integrated solutions, regulatory readiness, and demonstrable clinical benefits tied to recovery and throughput metrics.

Actionable recommendations for manufacturers, distributors, and clinical leaders to fortify supply chains, align product portfolios to workflows, and enhance regulatory and commercial readiness

Industry leaders should prioritize a set of practical actions to strengthen resilience, drive adoption, and capture value across clinical settings. First, invest in supply chain transparency and supplier diversification to reduce exposure to cross-border tariff and customs volatility, and consider regional manufacturing or toll-manufacturing arrangements to improve responsiveness. Next, design product portfolios that align with hospital and ambulatory workflows by offering formulation variants-such as ready-to-use solutions and pre-valved cartridges-and certifying compatibility with both machine and handheld vaporizer platforms.

Operationally, develop bundled service offerings that include training, maintenance, and consumable logistics to simplify decision-making for procurement teams. Build regulatory and environmental reporting capabilities to anticipate evolving impurity controls and emissions-related policies, thereby reducing approval lag and compliance cost. Strengthen relationships with hospital pharmacies and wholesale distributors while expanding digital channel readiness for online pharmacy fulfillment where allowed. Finally, prioritize clinical evidence generation that links anesthetic selection and delivery modality to recovery time, patient throughput, and safety outcomes, and use that evidence to support integrated value propositions during formulary negotiations and purchasing discussions.

A blended research design combining primary clinical and procurement interviews, site observations, regulatory and technical review, and supply chain analysis to ensure triangulated insights

The research methodology blends primary qualitative engagement with quantitative document synthesis and regulatory review to form a robust, triangulated evidence base. Primary research included structured interviews with clinical anesthesiologists, perioperative nurses, hospital pharmacists, procurement leaders, and device engineers to capture operational realities, clinical preferences, and procurement constraints. These interviews were complemented by site visits to ambulatory centers and hospital perioperative units to observe device integration, workflow interactions, and real-world dosing and recovery patterns.

Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory guidance documents, manufacturing standards for inhalational agents, and technical specifications for vaporizer and delivery systems. Supply chain analysis mapped inbound raw material flows, production steps, and distribution modalities to identify potential chokepoints and tariff exposure nodes. Data validation incorporated cross-stakeholder triangulation to reconcile discrepancies between clinical practice and procurement records, and sensitivity checks ensured conclusions remained robust across plausible scenario variations. Throughout, ethical considerations and patient safety priorities informed how clinical evidence was interpreted and how recommendations were framed.

Synthesis of clinical, commercial, and operational imperatives that define preparedness strategies for stakeholders navigating evolving sevoflurane supply, regulation, and adoption dynamics

In conclusion, sevoflurane remains a cornerstone of modern anesthesia practice, but its commercial and operational context is shifting in response to technology, policy, and clinical workflow evolution. Stakeholders that proactively align product development and distribution strategies with segmentation realities-addressing end-user heterogeneity, application-specific needs, delivery mode preferences, patient age group considerations, channel requirements, and formulation demands-will be better positioned to meet institutional procurement criteria and clinician expectations. Concurrently, tariff dynamics and regional regulatory variance underscore the importance of supply chain resilience and adaptable manufacturing footprints.

The most effective strategies balance clinical evidence generation with pragmatic commercial design, including bundled service models, regulatory preparedness, and sustainability commitments. By integrating these elements into a cohesive approach, manufacturers and distributors can reduce operational risk, accelerate adoption across care settings, and support clinicians in delivering safe, efficient anesthetic care. Decision-makers should treat the insights presented here as a foundation for targeted follow-up analysis and implementation planning that reflect their organizational priorities and regional constraints.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Inhalation Sevoflurane Anaesthetic Agent Market, by Delivery Mode

  • 8.1. Handheld Vaporizer
  • 8.2. Machine Vaporizer
  • 8.3. Portable Inhaler

9. Inhalation Sevoflurane Anaesthetic Agent Market, by Patient Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Inhalation Sevoflurane Anaesthetic Agent Market, by Formulation

  • 10.1. Liquid Concentrate
  • 10.2. Pre Valved Cartridges
  • 10.3. Ready To Use Solutions

11. Inhalation Sevoflurane Anaesthetic Agent Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Clinics
    • 11.2.1. Human Clinics
    • 11.2.2. Veterinary Clinics
  • 11.3. Hospitals
    • 11.3.1. Private
    • 11.3.2. Public

12. Inhalation Sevoflurane Anaesthetic Agent Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Inhalation Sevoflurane Anaesthetic Agent Market, by Application

  • 13.1. Cardiac Surgery
  • 13.2. General Surgery
    • 13.2.1. Abdominal
    • 13.2.2. Ent
    • 13.2.3. Orthopedic
  • 13.3. Neurological Surgery
  • 13.4. Obstetrics And Gynecology
  • 13.5. Pediatric Surgery

14. Inhalation Sevoflurane Anaesthetic Agent Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Inhalation Sevoflurane Anaesthetic Agent Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Inhalation Sevoflurane Anaesthetic Agent Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Inhalation Sevoflurane Anaesthetic Agent Market

18. China Inhalation Sevoflurane Anaesthetic Agent Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. 3S Corporation
  • 19.6. AbbVie Inc.
  • 19.7. Aetos Pharma Private Limited
  • 19.8. Baxter International Inc.
  • 19.9. Cadila Healthcare Ltd.
  • 19.10. Central Glass Co., Ltd.
  • 19.11. Fresenius Kabi AG
  • 19.12. Halocarbon Products Corporation
  • 19.13. Hikma Pharmaceuticals PLC
  • 19.14. Jiangsu Hengrui Medicine Co., Ltd.
  • 19.15. Lunan Pharmaceutical Group Co., Ltd.
  • 19.16. Neon Laboratories Pvt. Ltd.
  • 19.17. Novartis AG
  • 19.18. Novartis India Limited
  • 19.19. Ocean Pharmaceutical Ltd.
  • 19.20. Piramal Enterprises Ltd.
  • 19.21. Raman & Weil Private Limited
  • 19.22. Salvavidas Pharmaceutical Pvt. Ltd.
  • 19.23. Sandoz Group AG
  • 19.24. Troikaa Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HANDHELD VAPORIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HANDHELD VAPORIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HANDHELD VAPORIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY MACHINE VAPORIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY MACHINE VAPORIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY MACHINE VAPORIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PORTABLE INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PORTABLE INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PORTABLE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY LIQUID CONCENTRATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY LIQUID CONCENTRATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY LIQUID CONCENTRATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PRE VALVED CARTRIDGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PRE VALVED CARTRIDGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PRE VALVED CARTRIDGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY READY TO USE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY READY TO USE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY READY TO USE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HUMAN CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HUMAN CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HUMAN CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CARDIAC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CARDIAC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CARDIAC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ABDOMINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ABDOMINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ABDOMINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY NEUROLOGICAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY NEUROLOGICAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY NEUROLOGICAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY OBSTETRICS AND GYNECOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY OBSTETRICS AND GYNECOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY OBSTETRICS AND GYNECOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PEDIATRIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PEDIATRIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PEDIATRIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GCC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. GCC INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. G7 INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. G7 INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 217. G7 INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. G7 INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 221. NATO INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. NATO INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. NATO INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 228. NATO INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. NATO INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA INHALATION SEVOFLURANE ANAESTHETIC AGENT MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)